Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.64 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 4/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946391 | 1.00 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL18574075 | 1.00 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL263726 | 0.92 | IMPDH2 (0.75) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL16508951 | 0.89 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14929515 | 0.88 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL18574074 | 0.88 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL30363045 | 0.88 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14946399 | 0.88 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL113725 | 0.85 | IMPDH2 (0.60) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14929339 | 0.85 | HPGD (0.72) | IMPDH2IMPDH1NT5EHINT1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | IMPDH2 170/4885IMPDH1 169/4885TAS1R3 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.